This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The clinical manifestations of Guillain-Barre syndrome occur within about 3 weeks of the onset of a viral illness in up to 60% of cases. Other possible antecedent events include Campylobacter and Mycoplasma pneumoniae infections (1). Early symptoms may include pain suggestive of nerve root irritation and paraesthesia of the legs and feet. Back pain is an occasional initial presentation.

The cranial nerves may be affected, most commonly, the facial nerve. Cranial nerves I and VIII are not affected. Facial weakness may precede other neurological findings. It is often unilateral and may be indistinguishable from Bell's palsy.

Muscle weakness evolves over a period of 3 to 21 days. It may be generalised, proximal in distribution, or commence distally and ascend. In severe cases, there is respiratory and bulbar involvement. Tendon reflexes are lost but plantar responses remain normal.

There may be autonomic involvement - fluctuating blood pressure, tachycardia and urinary retention.

Sensory signs are infrequent.

5% of patients develop chronic disease (CIDP) characterised by progressive or relapsing and remitting symptoms.

Reference:

(1): J Neuroimmunol 1999 Dec;100(1-2):74-97 Pathogenesis of Guillain-Barre syndrome. Hughes RA, Hadden RD, Gregson NA, Smith KJ.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.